// Account brief

Daiichi Sankyo

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 7 4 live 1 1
Research labs and data 8 4 live 2 3

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Daiichi Sankyo puts research labs and data slightly ahead of AI in drug discovery, scoring 8 out of 10 for priority on labs against 7 out of 10 for AI, with delivery at 4 out of 10 and the live stage in both. The company describes its Smart Lab programme as the base for AI-driven drug design and shows robotic lab work in operation in Japan, instruments with built-in AI, and experiment data stored as standard data products with results written to electronic notebooks. It also says it runs OpenFold-3 and other AI models for its researchers on the cloud and uses AI agents in bioinformatics work. In the last 12 months, two research labs and data commitments were made public (a new Shinagawa research building labelled Smart Lab, and two new Research Division units, Smart Research Laboratories I and II) and one AI in drug discovery commitment (a partner-announced expansion of a Turbine collaboration), against one and two in the year before. On 6 October 2026, three R&D roles were open in research labs and data, in instrument automation, in-house research software and automated synthesis, with SiLA 2, AWS and UNIX/Linux among the skills asked, and one in AI in drug discovery, a biomodality design scientist.

AI in drug discovery

What the company says: Priority 7

Identify next BGTs by 2030 ... 当社は、2030年までに次世代のBGTsを特定することを重要な戦略目標として位置づけております。 ... 国内外の研究拠点の拡充やAI・データ駆動型創薬の推進

[Ortent translation: We have set identifying next-generation BGTs by 2030 as an important strategic goal. ... expanding our research sites in Japan and overseas and advancing AI and data-driven drug discovery]

有価証券報告書 第21期 (Annual Securities Report FY2025, 1 Apr 2025-31 Mar 2026), 19 Jun 2026, p. 12

Expanding Drug Discovery Research Capabilities: ... Expanding and strategizing AI-driven drug discovery into multi-modality research ... AI-driven molecular design

FY2025 Financial Results and 5-Year Business Plan Presentation & Discussion (FY2026-FY2030), 11 May 2026, p. 69

Smart Lab: Enabling Competitive AI-driven Drug Discovery ... Seamless data feedback to molecular design AI ... Smart Lab is the cornerstone of AI-driven drug design success.

Science & Technology Day 2025, 16 Dec 2025, p. 85

Launched Smart Research Lab in San Diego to Accelerate Innovation ... Integrated robotic automation for end-to-end workflows ... DS’s first dedicated drug discovery base in the U.S.

Science & Technology Day 2025, 16 Dec 2025, p. 86

Launched Smart Research Lab in San Diego to Accelerate Innovation ... Integrated robotic automation for end-to-end workflows ... DS’s first dedicated drug discovery base in the U.S.

Science & Technology Day 2025, 16 Dec 2025, p. 86

日本発の創薬イノベーションに向け成長投資を拡大 ... リサーチDX ... スマートリサーチラボ: ... AI/ロボティクスの研究応用

[Ortent translation: Expanding growth investment for drug discovery innovation from Japan ... Research DX ... Smart Research Labs: ... research applications of AI and robotics]

Public-private council on drug discovery capability, document 3-10: drug discovery innovation from Japan through science and technology (Daiichi Sankyo submission, Japanese), 10 Jul 2026, p. 5

イノベーション加速のためサンディエゴにスマートリサーチラボを開設 ... AI駆動型創薬を支えるデータ生成の自動化 24時間365日の運用で創薬候補の選定を加速

[Ortent translation: Opening a Smart Research Lab in San Diego to accelerate innovation ... automating the data generation that supports AI-driven drug discovery. Running 24 hours a day, 365 days a year to speed up the selection of drug candidates]

Public-private council on drug discovery capability, document 3-10: drug discovery innovation from Japan through science and technology (Daiichi Sankyo submission, Japanese), 10 Jul 2026, p. 12

研究 DX の加速と創薬探索基盤の統合強化を 図り、データ駆動型の創薬探索を推進する。

[Ortent translation: We will accelerate research DX and strengthen the integration of our drug discovery platforms, to advance data-driven drug discovery.]

2026年4月1日付 組織改定について (Organisational changes effective 1 April 2026), 24 Feb 2026, p. 3

What it shows running: Delivery 4, live

OpenFold-3をはじめとする最先端のAIモデルを社内環境に導入し、研究者が利用できるアプリケーションとしてクラウド環境上で提供しています。

[Ortent translation: We have brought state-of-the-art AI models, starting with OpenFold-3, into our internal environment and provide them in the cloud as applications our researchers can use.]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026

大規模言語モデルによるヒト遺伝子データの分析 複雑で膨大な遺伝子情報を高性能Graphics Processing Unit(GPU)で処理し

[Ortent translation: Analysis of human genetic data with large language models. Complex and vast genetic information is processed on high-performance graphics processing units (GPUs) and]

DXを継続的に動かす基盤と体制 (DX enablers page), No printed date. Its content dates it to May 2026 or later, and we read it on 6 Oct 2026

AIエージェントをバイオインフォマティクス業務に導入し、生命科学データの探索・解析を効率化・高度化しています。実際のデータ解析業務を通じてその有用性を検証し

[Ortent translation: We have introduced AI agents into bioinformatics work, making the exploration and analysis of life science data more efficient and more advanced. We are testing their usefulness through real data analysis work and]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026

We’re laying the foundation for integrating generative AI into our workflows and building a rapid design-make-test-analyze (DMTA) cycle

Building a 'Smart Research Lab' for Tomorrow's Drug Discovery, 9 Dec 2025

Commitments made public in the last 12 months: 1

  • Turbine vLab virtual assays for ADC discovery: Collaboration expanded so that Turbine vLab virtual assays are applied to Daiichi Sankyo proprietary ADC discovery programmes. Expanded, announced, 24 Sep 2026. Published by: partner only.

Commitments made public in the year before: 2

  • Nosis Bio research collaboration and option (Connexa AI platform): Research collaboration and option agreement to develop cell-targeted RNA medicines using the Nosis Connexa AI-powered drug design and delivery platform. New, announced, 11 Mar 2025. Published by: partner only.
  • Smart Research Laboratory (SRL), San Diego: Company established a San Diego laboratory for robotics, automation and software that generate discovery data and support AI-based approaches; full operations were later stated as planned for 2026. New, in build, 21 Jan 2025. Published by: company.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 1

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Research labs and data

What the company says: Priority 8

Expanding Drug Discovery Research Capabilities: Creation of BGTs through the integration of expanded research functions, digital transformation (DX) of drug discovery research, and open innovation

FY2025 Financial Results and 5-Year Business Plan Presentation (FY2026-FY2030), 11 May 2026, p. 69

Opening of Smart Research Lab San Diego ... Building AWS infrastructure and data utilization systems ... Completion of new research building (Smart Lab)

FY2025 Financial Results and 5-Year Business Plan Presentation (FY2026-FY2030), 11 May 2026, p. 69

Launched Smart Research Lab in San Diego to Accelerate Innovation ... Integrated robotic automation for end-to-end workflows ... DS’s first dedicated drug discovery base in the U.S.

Science & Technology Day 2025, 16 Dec 2025, p. 86

Dr. Takeshi Isoyama, head of lab smartification, has overseen the project ... The laboratory comprises of more than twenty members

Our Stories: Advancing Research for the Future - The Potential of Smart Research Laboratories in Research DX, 31 Oct 2025

研究 DX と創薬探索研究基盤の機能集約と強化を図るため ... 『スマートリサーチ第一研究所』 ... を新設する。

[Ortent translation: To consolidate and strengthen research DX and the drug discovery research platform ... "Smart Research Laboratory I" ... will be newly established.]

2026年4月1日付 組織改定について (organisation change effective 1 April 2026, Japanese), 24 Feb 2026, p. 3

日本発の創薬イノベーションに向け成長投資を拡大 ... リサーチDX ... スマートリサーチラボ: ... AI/ロボティクスの研究応用

[Ortent translation: Expanding growth investment for drug discovery innovation from Japan ... Research DX ... Smart Research Labs: ... research applications of AI and robotics]

Public-private council on drug discovery capability, document 3-10: drug discovery innovation from Japan through science and technology (Daiichi Sankyo submission, Japanese), 10 Jul 2026, p. 5

Identify next BGTs by 2030 ... 当社は、2030年までに次世代のBGTsを特定することを重要な戦略目標として位置づけております。 ... 国内外の研究拠点の拡充やAI・データ駆動型創薬の推進

[Ortent translation: We have set identifying next-generation BGTs by 2030 as an important strategic goal. ... expanding our research sites in Japan and overseas and advancing AI and data-driven drug discovery]

有価証券報告書 第21期 (Annual Securities Report FY2025, 1 Apr 2025-31 Mar 2026), 19 Jun 2026, p. 12

What it shows running: Delivery 4, live

実験装置にAIを組み込み、これまで人が目視で行っていた液体の量の測定や ... リアルタイムで自動的に行えるようになりました。これにより、実験操作の一部が自動化され、作業の正確性と効率が向上しています。

[Ortent translation: AI has been built into laboratory equipment, so that measuring liquid volumes, which people used to do by eye, ... can now be done automatically in real time. Part of the experimental work is now automated, which has improved its accuracy and efficiency.]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026

研究者が設計した多様な実験工程をロボットで実行します。 ... 「メタデータ」を取得し、実験結果とともにデータプロダクトとして標準化して保存します。実験結果を電子ノートへまとめる仕組みも整備しています。

[Ortent translation: Robots carry out the varied experimental steps our researchers design. ... "metadata" is captured and stored, standardised as a data product together with the experimental results. We have also set up a system to compile experimental results into electronic notebooks.]

DX - データと先進デジタル技術の活用 (DX corporate page), No printed date. Its content dates it to Jul 2026 or later, and we read it on 6 Oct 2026

At the SRL, advanced robotics and in-house developed, sophisticated software is being utilized to significantly enhance the efficiency of drug discovery research

Advancing Research for the Future: The Potential of Smart Research Laboratories in Research DX, 31 Oct 2025

イノベーション加速のためサンディエゴにスマートリサーチラボを開設 ... AI駆動型創薬を支えるデータ生成の自動化 24時間365日の運用で創薬候補の選定を加速

[Ortent translation: Opening a Smart Research Lab in San Diego to accelerate innovation ... automating the data generation that supports AI-driven drug discovery. Running 24 hours a day, 365 days a year to speed up the selection of drug candidates]

Public-private council on drug discovery capability, document 3-10: drug discovery innovation from Japan through science and technology (Daiichi Sankyo submission, Japanese), 10 Jul 2026, p. 12

2025年1月、米国カリフォルニア州サンディエゴに 「スマートリサーチラボ (SRL) 」 を設立しました。...2026年の稼働を目指し、創薬のスピードと質を飛躍的に高めるための基盤づくりを進めています。

[Ortent translation: In January 2025 we established the Smart Research Lab (SRL) in San Diego, California. ... Aiming to start operation in 2026, we are building the foundation to greatly improve the speed and quality of drug discovery.]

株主通信 Vol.27 2025年12月号 (shareholder newsletter, Japanese), Dec 2025, p. 3

Our first key milestone is getting the lab fully operational.

Building a 'Smart Research Lab' for Tomorrow's Drug Discovery, 9 Dec 2025

Commitments made public in the last 12 months: 2

Commitments made public in the year before: 1

  • Smart Research Laboratory (SRL), San Diego: Company established a San Diego laboratory for robotics, automation and software that generate discovery data and support AI-based approaches; full operations were later stated as planned for 2026. New, in build, 21 Jan 2025. Published by: company.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Technology named in these postings

Asked for as experience: SiLA 2, AWS, UNIX/Linux.

A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.

Two questions to investigate (Ortent's interpretation)

  1. Lab automation and lab software roles sit in Smart Research Laboratories I and II in Shinagawa, while the San Diego laboratory, a cloud centre of excellence in the Digital & Technology department and the global Data Foundation and AI-ML department also support discovery research. What is each unit's remit for lab automation, orchestration software and research data systems, and who decides on equipment and software vendors?
  2. The external AI discovery work found here was announced by partners (Nosis and Turbine), while internally Daiichi Sankyo runs OpenFold-3 on the cloud and is hiring to build its own modality design platform. Who decides whether to adopt an external AI discovery platform or build in-house, does that go through open innovation, the research units or digital procurement, and how is it funded within the 2026 to 2030 business plan?

Coverage limits

Daiichi Sankyo publishes results webcasts rather than text transcripts, and these were not reviewed, so that source is partial. Business Wire and several partner and trade sites blocked access, and no Japanese-language web search was run, so Japanese-only partner releases and trade press may be under-covered. The Value Report 2026 was not yet published, and several items rest on undated pages, so they are not counted in either year. It is not established whether the in-house OpenFold-3 use comes through consortium membership.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call